Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26960938
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Falagas ME
; Vouloumanou EK
; Samonis G
; Vardakas KZ
Clin Microbiol Rev
2016[Apr]; 29
(2
): 321-47
PMID26960938
show ga
The treatment of bacterial infections suffers from two major problems: spread of
multidrug-resistant (MDR) or extensively drug-resistant (XDR) pathogens and lack
of development of new antibiotics active against such MDR and XDR bacteria. As a
result, physicians have turned to older antibiotics, such as polymyxins,
tetracyclines, and aminoglycosides. Lately, due to development of resistance to
these agents, fosfomycin has gained attention, as it has remained active against
both Gram-positive and Gram-negative MDR and XDR bacteria. New data of higher
quality have become available, and several issues were clarified further. In this
review, we summarize the available fosfomycin data regarding pharmacokinetic and
pharmacodynamic properties, the in vitro activity against susceptible and
antibiotic-resistant bacteria, mechanisms of resistance and development of
resistance during treatment, synergy and antagonism with other antibiotics,
clinical effectiveness, and adverse events. Issues that need to be studied
further are also discussed.
free
free
free
